CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 1, 2009, Pages 240-248

  Parlevliet, Edwin T ^a   Schröder van der Elst, Janny P ^a   Corssmit, Eleonora P M ^a   Picha, Kristen ^d   O'Neil, Karyn ^d   Stojanovic Susulic, Vedrana ^d   Ort, Tatiana ^d   Havekes, Louis M ^a,b,c,e   Romijn, Johannes A ^a   Pijl, Hanno ^a,b,c  

^a Department of Endocrinology and Metabolic Diseases ^*  (Netherlands)

^b Internal Medicine   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CENTOCOR INC   (United States)

^e TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CNTO 736; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; HYBRID PROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPOPROTEIN METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANIMAL; ANIMAL FOOD; BLOOD; C57BL MOUSE; CYTOMEGALOVIRUS; DRUG EFFECT; DRUG POTENTIATION; FAT INTAKE; GENETICS; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINISM; INTRAVENOUS DRUG ADMINISTRATION; LIVER; METABOLISM; MOLECULAR CLONING; PHYSIOLOGY; PROMOTER REGION;

ANIMAL FEED; ANIMALS; BLOOD GLUCOSE; CLONING, MOLECULAR; CYTOMEGALOVIRUS; DIETARY FATS; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINISM; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN RESISTANCE; LIPOPROTEINS, VLDL; LIVER; MICE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; RECEPTORS, GLUCAGON; RECOMBINANT FUSION PROTEINS; TRIGLYCERIDES;

EID: 59149099913     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.144154     Document Type: Article

References (39)

1. Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, and Breslow JL (1992) Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 90:1889-1900.
2. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, and Bloom SR (2005) The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044:127-131.
3. Adiels M, Borén J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Packard C, and Taskinen MR (2005) Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterio-scler Thromb Vasc Biol 25:1697-1703.
4. Bond A (2006) Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc (Bayl Univ Med Cent) 19:281-284.
5. Bullock BP, Heller RS, and Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968-2978.
6. Costa J, Borges M, David C, and Vaz Carneiro A (2006) Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332:1115-1124.
7. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, and Holst JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131.
8. Furuse M, Matsumoto M, Mori R, Sugahara K, Kano K, and Hasegawa S (1997) Influence of fasting and neuropeptide Y on the suppressive food intake induced by intracerebroventricular injection of glucagon-like peptide-1 in the neonatal chick. Brain Res 764:289-292.
9. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes DG, and Young AA (2005) Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glyce-mia and body weight. Endocrinology 146:2069-2076.
10. Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, and Flatt PR (2006) Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J Pharmacol Exp Ther 318:914-921.
11. Holst JJ, Orskov C, Nielsen OV, and Schwartz TW (1987) Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169-174.
12. Huang XF, Han M, and Storlien LH (2003) The level of NPY receptor mRNA expression in diet-induced obese and resistant mice. Brain Res Mol Brain Res 115:21-28.
13. Hussain MM, Shi J, and Dreizen P (2003) Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 44:22-32.
14. Ikezawa Y, Yamatani K, Ohnuma H, Daimon M, Manaka H, and Sasaki H (2003) Glucagon-like peptide-1 inhibits glucagon-induced glycogenolysis in perivenous hepatocytes specifically. Regul Pept 111:207-210.
15. Julius U (2003) Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp Clin Endocrinol Diabetes 111:246-250.
16. Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L, and Efendic S (1996) The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 19:1200-1206.
17. Kreymann B, Williams G, Ghatei MA, and Bloom SR (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304.
18. Larsen PJ, Tang-Christensen M, Holst JJ, and Orskov C (1997) Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77:257-270.
19. Lugari R, Dei Cas A, Ugolotti D, Finardi L, Barilli AL, Ognibene C, Luciani A, Zandomeneghi R, and Gnudi A (2002) Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res 34:150-154.
20. Márquez L, Trapote MA, Luque MA, Valverde I, and Villanueva-Peñacarrillo ML (1998) Inositolphosphoglycans possibly mediate the effects of glucagon-like pep-tide-1(7-36)amide on rat liver and adipose tissue. Cell Biochem Funct 16:51-56.
21. Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, and Taskinen MR (2006) Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetolo-gia 49:2049-2057.
22. Meier JJ, Gethmann A, Götze O, Gallwitz B, Holst JJ, Schmidt WE, and Nauck MA (2006) Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabeto-logia 49:452-458.
23. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, and Niijima A (1996) Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 271:E808-E813.
24. Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, and Schmiegel W (1998) Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med 15:937-945.
25. Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, Niijima A, and Uchida K (2000) The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 80:14-21.
26. O'Neil KT and Picha KM (2005), inventors; Centocor Inc., assignee. Human GLP-1 mimetibodies, compositions, methods and uses. World Patent WO2005097175A2. 2005 Oct 10.
27. Picha KM, Cunningham MR, Drucker DJ, Mathur A, Ort T, Scully M, Soderman A, Spinka-Doms T, Stojanovic-Susulic V, Thomas BA, et al. (2008) Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes 57:1926-1934.
28. Prodi E and Obici S (2006) Minireview: the brain as a molecular target for diabetic therapy. Endocrinology 147:2664-2669.
29. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, and Feinglos MN (1988) Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163-1167.
30. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, and Holst JJ (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723.
31. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72.
32. van den Hoek AM, Heijboer AC, Corssmit EP, Voshol PJ, Romijn JA, Havekes LM, and Pijl H (2004a) PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 53:1949-1952.
33. van den Hoek AM, Voshol PJ, Karnekamp BN, Buijs RM, Romijn JA, Havekes LM, and Pijl H (2004b) Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes 53:2529-2534.
34. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, and Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613.
35. Wilding JP, Gilbey SG, Bailey CJ, Batt RA, Williams G, Ghatei MA, and Bloom SR (1993) Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse. Endocrinology 132:1939-1944.
36. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, and Nauck MA (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332.
37. Yamato E, Ikegami H, Takekawa K, Fujisawa T, Nakagawa Y, Hamada Y, Ueda H, and Ogihara T (1997) Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1). Horm Metab Res 29:56-59.
38. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, and Denaro M (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034.
39. Zander M, Madsbad S, Madsen JL, and Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830.